AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 162 min read$ACOG

Opaleye Management Inc. purchased $46K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 7,685 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $5.96 ($5.91–$5.99) across 3 trades over 2026-06-11 to 2026-06-15.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Jun 16, 2026, 12:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase (indirect) by a 10% owner over 2026-06-11 to 2026-06-15, totaling ~$45.8K at ~$5.96/share.

02

Market read

Traders may treat this as a small sentiment input, but it lacks the scale or accompanying fundamentals to drive a sustained repricing.

03

What to watch

No 10b5-1 plan is cited; however, the filing does not explain intent, and the transaction window spans only a few days with modest share count.

Relevance 4/10Novelty 6/10Timing: filed 2026-06-15T20:10:31-04:00 (after market)

Background

The article is an SEC Form 4 insider transaction disclosure for Alpha Cognition Inc. (ACOG).

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. (10% owner) filed an SEC Form 4 showing an indirect open-market purchase of 7,685 ACOG shares for ~$45.8K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than valuation.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction value (~$45.8K) is relatively small and there is no accompanying operational or financial update.

Market effects

Sector

No sector-level implications; this is company-specific ownership activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Indirect 10% owner buying on a small dollar amount may reflect routine portfolio management or diversification rather than a strong bullish signal.

Key entities

  • issuer
    Alpha Cognition Inc.

    Subject of the Form 4 insider transaction; shares purchased indirectly by a 10% owner.

  • insider
    Opaleye Management Inc.

    10% owner reporting an indirect open-market purchase of ACOG shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

AUG 15
$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com6 min
AUG 14
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com4 min
JUL 29
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com3 min